Louisiana enacted legislation June 12 establishing new commercial reimbursement requirements for pharmacy benefit managers. The law creates a commercial market reimbursement floor and includes provisions intended to prevent PBMs from shifting costs to patients. Act 913, signed into law June…
Pharmacy
CMS will discontinue the Part D premium stabilization program at the end of this year, returning the standalone prescription drug plan market to what the agency called “traditional market conditions.” CMS said July 28 its analysis of 2027 bids indicated…
Pharmacies in the Pittsburgh area are reporting shortages of estradiol patches used to treat menopause, perimenopause and gender dysphoria, according to a July 29 Pittsburgh Post-Gazette report. Pharmacists told the newspaper the supply constraints have lasted for months, with some…
Federal policy changes could reshape pharmacy reimbursement, drug pricing and hospital operations in 2027, according to a new Vizient outlook. The report, published July 27, highlights four pharmacy developments health systems should monitor as they plan for the year ahead.…
The FDA has published 17 revised draft product-specific guidances for peptide products, updating its recommendations for the development and assessment of certain generic peptide drugs. The revised draft guidances address the following peptide products, according to a July 28 agency…
Advertisement
Becker’s asked pharmacy executives from hospitals and health systems, along with academic medical centers and universities across the U.S. to share the biggest shifts they’re seeing in patient expectation. The 17 executives featured in this article are all speaking at…
The FDA approved Simtriyo (centanafadine), making it the first and only approved norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI) for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients aged 6 years and older weighing at least 20 kilograms, according…
Betting platforms Kalshi and Polymarket are now taking wagers on whether the FDA will approve treatments for lung, breast, pancreatic and blood cancers this year, with Kalshi also planning to let users bet on clinical trial outcomes. Kalshi launched the…
A federal court has denied North Dakota’s request to pause enforcement of a ruling that struck down its 340B drug pricing law while the state appeals, according to a July 27 court order. The U.S. District Court for the District…
An FDA advisory committee is scheduled to review Capricor Therapeutics’ cell therapy deramiocel after agency reviewers concluded the available clinical data do not provide substantial evidence that the treatment is effective for Duchenne muscular dystrophy. FDA reviewers said the phase…